Riverwater Partners LLC Acquires 29,109 Shares of Haemonetics Co. (NYSE:HAE)

Riverwater Partners LLC boosted its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 185.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 44,841 shares of the medical instruments supplier's stock after acquiring an additional 29,109 shares during the quarter. Haemonetics accounts for about 1.8% of Riverwater Partners LLC's portfolio, making the stock its 10th biggest holding. Riverwater Partners LLC owned 0.09% of Haemonetics worth $3,556,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in HAE. Allspring Global Investments Holdings LLC increased its stake in Haemonetics by 75.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier's stock worth $63,933,000 after buying an additional 343,214 shares in the last quarter. Cardinal Capital Management increased its position in shares of Haemonetics by 17.0% during the third quarter. Cardinal Capital Management now owns 17,349 shares of the medical instruments supplier's stock worth $1,395,000 after purchasing an additional 2,517 shares in the last quarter. Vontobel Holding Ltd. raised its stake in Haemonetics by 3.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 4,878 shares of the medical instruments supplier's stock valued at $392,000 after purchasing an additional 180 shares during the last quarter. Inspire Investing LLC lifted its holdings in Haemonetics by 19.7% in the 3rd quarter. Inspire Investing LLC now owns 5,130 shares of the medical instruments supplier's stock valued at $412,000 after purchasing an additional 845 shares in the last quarter. Finally, West Coast Financial LLC boosted its stake in Haemonetics by 2.2% during the 3rd quarter. West Coast Financial LLC now owns 47,182 shares of the medical instruments supplier's stock worth $3,792,000 after purchasing an additional 1,013 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HAE has been the topic of several research reports. Barrington Research reissued an "outperform" rating and issued a $108.00 price target on shares of Haemonetics in a research note on Monday, September 23rd. JMP Securities restated a "market outperform" rating and set a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. Citigroup decreased their target price on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating on the stock in a report on Thursday, August 22nd. Bank of America began coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They issued a "neutral" rating and a $85.00 target price on the stock. Finally, CL King started coverage on Haemonetics in a research note on Friday, September 13th. They issued a "buy" rating and a $116.00 price objective for the company. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $106.14.

Haemonetics Stock Up 3.4 %

Shares of NYSE:HAE traded up $2.47 during trading on Thursday, hitting $75.76. The company's stock had a trading volume of 634,690 shares, compared to its average volume of 536,951. The company has a market capitalization of $3.86 billion, a PE ratio of 33.10, a P/E/G ratio of 1.19 and a beta of 0.30. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $97.97. The business has a 50 day moving average price of $75.67 and a two-hundred day moving average price of $83.35.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, missing the consensus estimate of $1.03 by ($0.01). The company had revenue of $336.17 million for the quarter, compared to analysts' expectations of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. Haemonetics's revenue for the quarter was up 8.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.05 EPS. As a group, research analysts expect that Haemonetics Co. will post 4.57 EPS for the current fiscal year.

Insider Activity

In other Haemonetics news, insider Stewart W. Strong sold 4,312 shares of Haemonetics stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $91.15, for a total transaction of $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares of the company's stock, valued at $1,658,565.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.80% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.